Regeneron Pharmaceuticals, Inc.
REGNFull coverage—Regeneron Pharmaceuticals, Inc.
REGNNasdaqFull coverage
Q3 fiscal 2026 edition
A free account unlocks one dossier edition a month.
Create a free accountAlready have an account? Sign in
Summary
Free to read
Regeneron invents antibody medicines and earns either by selling them itself, as with the eye drug EYLEA HD and the cancer drug Libtayo, or by taking a share of Sanofi's profit on Dupixent, which is now about half of its revenue. Third-quarter 2026 revenue rose 36% to $5.12 billion, but about a quarter of the jump in the Dupixent profit share came from the end of a repayment to Sanofi, and underlying growth was about 26%. EYLEA HD is holding the US eye franchise roughly flat while copies of the original EYLEA multiply. Moatsight estimates revenue of about $21.2 billion over the next four quarters, including a $1.0 billion up-front payment from Sanofi, and the open question is whether rising research spending yields medicines large enough to replace Dupixent once its main US patent expires in 2031.
In the full dossier
- Part 1In brief
- Part 2Business explainer
- Part 3Earnings
- Part 4Valuation and projections
- Part 5What changed
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers